0      0

73547 - Session I: Molecular Design, Developability and Biotransformation

‐ Sep 6, 2023 11:50am

Session Speakers:

Importance of Disulfide Bond re-arrangement in vitro and in vivo: Evidence and Approaches to Address It
Franta Hubálek, Novo Nordisk A/S

Development of a Rapid and Automated, Compliance Ready Workflow for Full Sequence Coverage of RNAi Therapeutics
Jennifer Nguyen, Alnylam Pharmaceuticals

Elucidation, Characterization and Monitoring of a Unique Tyrosine Sulfation Post-Translational Modification During Bispecific Antibody Process Development and Scaleup
David Mahon, Bristol-Myers Squibb Company

You must be logged in and own this session in order to post comments.